Plaque Calcium Characterization and Ruptured Plaques
Launched by LI MIN · Feb 20, 2019
Trial Information
Current as of August 20, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new imaging technique called ultrashort echo time (UTE) MRI, which helps doctors see and measure calcium buildup in the arteries, particularly in patients with vulnerable plaques that may lead to serious heart problems. The researchers want to find out if this advanced imaging can help identify patients who are at higher risk for complications and if it can distinguish between those who have symptoms and those who do not.
To participate in the study, individuals must be scheduled for a procedure to clear blocked carotid arteries, either through surgery or a stent. However, people with certain conditions, such as having metal implants like pacemakers or experiencing severe anxiety in confined spaces, cannot join. Participants will undergo UTE MRI scans, which are non-invasive and aim to provide valuable information about their arterial health. This research could lead to better ways to predict and manage heart disease in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients referred for carotid endarterectomy or stent were prospectively enrolled.
- Exclusion Criteria:
- • Patients with ferromagnetic metal, active implants such as pacemakers, aneurysm clips, known claustrophobia, and those who were unable to provide informed consent were excluded from enrollment.
About Li Min
Li Min is a leading clinical trial sponsor dedicated to advancing medical research and innovation. With a strong focus on developing groundbreaking therapies, Li Min collaborates with healthcare professionals and research institutions to conduct rigorous clinical trials across various therapeutic areas. Committed to upholding the highest standards of ethical practice and regulatory compliance, Li Min prioritizes patient safety and scientific integrity. Through its comprehensive approach to clinical development, Li Min aims to bring transformative solutions to market, ultimately improving patient outcomes and enhancing the quality of healthcare globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Jinan, Shandong, China
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials